AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01654653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypertonic sodium lactate
Description: Administered at beginning of surgery as loading dose at 3 mL/kg body weight within 15 minutes. Additional fluid administered if needed and this was was managed similarly in both groups; the types and amount of additional fluid was measured and recorded. Surgery procedure and concomitant medication was managed similarly.
Study NCT01654653 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 6% Hydroxy Ethyl Starch
Description: Administered at beginning of surgery as loading dose at 3 mL/kgBW within 15 minutes. Additional fluid given if needed and this was managed similarly in both groups; the types and amount of additional fluid was measured and recorded. Surgery procedure and concomitant medication was managed similarly
Study NCT02615015 — intervention group
Intervention type: OTHER
Intervention: Blood draw
Study NCT00420277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemospan (MP4OX)
Description: 250 mL unit dose, up to 500 mL total dose as needed at protocol-defined dosing triggers
Study NCT00420277 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Voluven (HES 130/0.4)
Description: 250 mL unit dose, up to 500 mL total dose as needed at protocol-defined dosing triggers
Study NCT02952989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGN-2FF
Description: SGN-2FF oral daily dosing.
Study NCT02952989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: 200 mg every 3 weeks by IV infusion
Study NCT02951845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54416076 (Oral Suspension)
Description: Participants will receive (25 mg) oral suspension of JNJ-54416076 in Part 1 and Part 2.
Study NCT02951845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54416076 (Formulation 1: Direct Compression Tablets)
Description: Participants will receive JNJ-54416076 Tablet formulation 1 (5\*5 mg Tablets \[25 mg total\]) under fasted and fed condition in Part 1.
Study NCT02951845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54416076 (Formulation 2: Fluid Bed Granulation Tablets)
Description: Participants will receive JNJ-54416076 Tablet formulation 2 (5\*5 mg Tablets \[25 mg total\]) under fasted and fed condition in Part 2.
Study NCT03541954 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Sensory testing of lower urinary tract.
Description: Non invasive lower urinary tract sensitivity testing: provoked diuresis with sonographic estimates of sensory thresholds.
Study NCT03541954 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Sensory testing of lower rectal tract
Description: Lower digestive tract sensitivity testing: rectal electronic barostat with ascending pressure (phasic distension).
Study NCT03541954 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Sensory testing of vulva muscles
Description: Vulvar sensitivity testing: pressure pain threshold evaluated using vulvagesiometer.
Study NCT03541954 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Sensory testing of pelvic muscles
Description: Myofascial sensitivity testing: piriformis, levator ani and obturator internus muscles pressure pain threshold evaluated using intra-vaginal algometer.
Study NCT01820507 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optiflow (Fisher&Paykel)
Description: The described method of oxygen supply will be maintained continuously for the first 24 hours after extubation.
Study NCT01820507 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal cannulae or controlled oxygen concentration mask
Description: The described method of oxygen supply will be maintained continuously for the first 24 hours after extubation.
Study NCT02252900 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging
Description: All patients will undergo the diagnostic test specific to the study
Study NCT01296542 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin Ophthalmic
Study NCT01296542 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Besifloxacin Ophthalmic
Study NCT00474786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Subjects randomized to arm B will take sorafenib 400 mg (2 x 200 mg tablets) PO, BID (total daily dose of 800 mg).
Study NCT00474786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temsirolimus (Torisel)
Description: Subjects randomized to arm A will receive temsirolimus (Torisel) 25 mg via IV infusion once weekly. This infusion is to be administered over a 30-60 minute period. Subjects are to be pre-treated with 25-50 mg IV diphenhydramine (or comparable IV antihistamine) approximately 30 minutes before temsirolimus infusion.
Study NCT03885180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin Sodium
Description: Extending warfarin anticoagulation
Study NCT02756780 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tenovus Cancer Choir
Description: Choir sessions will take place at both of the Royal Marsden Hospital sites on a weekly basis. Sessions typically consist of learning popular songs with messages of support. Songs are learnt without sheet music, using specially created backing tracks. These are also made available to participants at home so they can continue singing away from the sessions. No singing experience is required and the main aim of the sessions is enjoyment and meeting other people. Sessions will take place in the early evening so that participants have the option of staying to socialise afterwards.
Study NCT03369028 — intervention group
Intervention type: OTHER
Intervention: 2D and 3D image of infants´ faces
Description: 2D and 3D image of infants´ faces
Study NCT00725790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vardenafil
Description: 10 mg vardenafil on demand treatment for first 4 weeks.~A decision is made at week 4 to either maintain the previous dosage regimen or to up-titrate to 20 mg per dose of vardenafil or down-titrate to 5 mg per dose of vardenafil during the subsequent 4 week double-blind treatment period.~A decision is made at week 8 to either maintain the previous dosage regimen or to up-titrate to 20 mg per dose of vardenafil or down-titrate to 5 mg per dose of vardenafil during the subsequent 4 week double-blind treatment period.
Study NCT00725790 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10 mg placebo on demand treatment for first 4 weeks.~A decision is made at week 4 to either maintain the previous dosage regimen or to up-titrate to 20 mg per dose of placebo or down-titrate to 5 mg per dose of placebo during the subsequent 4 week double-blind treatment period.~A decision is made at week 8 to either maintain the previous dosage regimen or to up-titrate to 20 mg per dose of placebo or down-titrate to 5 mg per dose of placebo during the subsequent 4 week double-blind treatment period.
Study NCT04537117 — intervention group
Intervention type: OTHER
Intervention: Questionaire
Description: Questionnaire addressing pediatric dentists behaviors and practices during the COVID-19 pandemic
Study NCT03347734 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eye exercises group
Description: * 20 times hot water, 20 times cold water washing face in the morning and evening.~* Palming; 2 hands are rubbed together and warmed up, and the eyes are closed, and 8 digits are drawn with eyes in darkness.~* 20 blinks~* Looking at a clock in a circular shape, from 12 to 6, from 6 to 12, from 3 to 9, from 9 to 3, from 2 to 8, from 8 to 2, oblique from 10 to 4, from 4 to 10, and turning the eyes starting from 12 clockwise and counterclockwise. At the end of the exercises, 2-3 minutes of light massage around the eyes and on sunny days, sunbathing was recommended by closing the eyes for 3-5 minutes and swinging to the left and right.
Study NCT03347734 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Convergence exercise group
Description: * Close eyes for 15 s,~* Focus on a point 1 to 1.5 ft away for 10 s,~* Close eyes for 5 s,~* Focus on a point 20 ft away for 10 s,~* Close eyes for 5 s,~* Focus on a point 1 to 1.5 ft away for 10 s,~* Blink for 5 s,~* Close eyes for 5 s.
Study NCT03347734 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Oculomotor Exercise Group (OMEG)
Description: * The saccadic eye movement exercise included moving the eyes horizontally between two stationary targets while keeping the head still.~* The smooth pursuit exercise included moving the target horizontally and tracking it with the eyes while keeping the head still.~* The adaptation X1 exercise included moving the head horizontally while keeping the stationary target in focus.~* The adaptation X2 exercise included moving the head and target in opposite directions horizontally while tracking the target with the eyes.
Study NCT01828333 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT03713008 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Fluid bolus
Description: All patients included in the study will receive 5 ml/kg fluid bolus of a balanced crystalloid solution.
Study NCT02290834 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive, functional and subjective assessments
Description: Cognitive and functional assessments
Study NCT02290834 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MRI
Description: Magnetic Resonance Imaging (MRI) Scan
Study NCT03707873 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: Education + Medication adherence monitoring + Feedback when low adherence
Study NCT03812081 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Group A : Baska Mask Airway
Description: Size selection is based on the manufacturer's recommendation of weight-based estimate plus clinical judgment. The Baska Mask is available in four sizes: size three (30 to 50 kg), size four (50 to 70 kg), size five (70 to 100 kg),The membranous cuff of the Baska Mask appears bulkier than the equivalent inflatable cuff on cuffed laryngeal masks. The mask can easily be decreased in size during insertion by compressing the proximal, firmer part of the mask below the airway tube, between the thumb and two fingers
Study NCT03812081 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Group B: Proseal Laryngeal Mask Airway
Description: Proseal LMA (size 3,4,5) was used for ventilation according of patient body weight.Size selection is based on the manufacturer's recommendation of weight-based estimate plus clinical judgment.
Study NCT01958281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF
Description: Tablet(s) administered orally once daily
Study NCT01958281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: 200 mg tablet administered orally once daily
Study NCT02290834 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: PET Scan
Description: Positron Emission Tomography (PET) Scan
Study NCT01958281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: 90/400 mg fixed-dose combination (FDC) tablet administered orally once daily
Study NCT04115917 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Schocket scleral depressor
Description: Scleral Depression on eye with Schocket scleral depressor
Study NCT04115917 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cotton tipped applicator
Description: Scleral Depression on eye with cotton tipped applicator
Study NCT03653949 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational intervention
Description: It will be an interactive lecture, 60 minutes long. The class will cover physiopathology, complications, treatment and prevention of exacerbations. Audiovisual resources and practical demonstrations of usual care will be used. Individual questions will be answered during the class.
Study NCT03653949 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational intervention
Description: It will be an interactive lecture, 60 minutes long. The class will cover physiopathology, complications, treatment and prevention of exacerbations. Audiovisual resources and practical demonstrations of usual care will be used. Individual questions will be answered during the class.
Study NCT03653949 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: The aerobic exercise program will be performed at home, on a cycle ergometer for lower limbs between 24 and 35 minutes: 5 minutes of warm-up, 14 to 25 minutes of high-intensity interval exercise and 5 minutes of cool down.
Study NCT02350946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Study NCT02350946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT01798407 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Activa Tremor Control Sys (DBS Implant)
Description: DBS system consists of the Activa RC 37612 System (Implantable Pulse Generator with Model 37085 Extensions (40 to 95cm), Activa Patient Programmer, and Medtronic Model 3389 DBS Lead). This system is commercially approved for the treatment of chronic, intractable Parkinson's Disease. It will be used with the Model SP-10344 Memory Mod Software which enables the physician to program the Implantable Pulse Generator to a higher frequency.
Study NCT01798407 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Randomized, staggered withdrawal phase
Description: For responders only: double blind discontinuation will be attempted on either the 12 or 13 month visit. Stimulation intensity will be decreased by 50% and then completely discontinued two weeks later. Subjects will be seen biweekly until 15 months post activation or escape criteria are met. These escape criteria include relapse at 2 visits, hospitalization, active suicidal ideation, or withdrawing consent. If any of these criteria are met, the blind will be broken and open treatment will be resumed.
Study NCT03419598 — intervention group
Intervention type: PROCEDURE
Intervention: Opening wedge high tibial osteotomy
Description: Realignment of knee by creating an opening wedge osteotomy in the upper part of the tibia. Since this is a virtual trial, the virtual patients were duplicated and enrolled into both arms
Study NCT03419598 — intervention group
Intervention type: DEVICE
Intervention: Personalised subject specific custom HTO plate
Description: Subject specific custom plate for stabilizing an open wedge HTO
Study NCT03419598 — intervention group
Intervention type: DEVICE
Intervention: Generic HTO plate
Description: Generic plate for stabilizing an open wedge HTO
Study NCT04843670 — intervention group
Intervention type: PROCEDURE
Intervention: duodenopancreatectomy
Description: resection of the head of the pancreas, the mower part of the biliary duct, and antrectomy
Study NCT02770950 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zushima plaster with high dose
Description: Patients in high dose Zushima plaster group will use Zushima plaster topically on knee(s) for 24h per day.
Study NCT02770950 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zushima plaster with low dose
Description: Patients in low dose Zushima plaster group will use Zushima plaster topically on knee(s) for 12h per day.
Study NCT02770950 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indometacin Cataplasms
Description: Patients in Indometacin Cataplasms group will use Indometacin Cataplasms on knee(s)for 24h per day.
Study NCT04632823 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Comprehensive Non-pharmacological Treatment Program
Description: dietary supplement, specific type of exercise, self-management education
Study NCT01193608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AAB-003 (PF-05236812)
Description: 0.5 mg/kg AAB-003, IV
Study NCT01193608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AAB-003 (PF-05236812)
Description: 1 mg/kg AAB-003, IV
Study NCT01193608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AAB-003 (PF-05236812)
Description: 2 mg/kg AAB-003, IV
Study NCT01193608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AAB-003 (PF-05236812)
Description: 4 mg/kg AAB-003, IV
Study NCT01193608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AAB-003 (PF-05236812)
Description: 8 mg/kg AAB-003, IV
Study NCT01193608 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, IV
Study NCT01714843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: linaclotide
Description: oral
Study NCT01714843 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral
Study NCT04097158 — intervention group
Intervention type: OTHER
Intervention: Sample Collection
Description: The investigators will be collecting blood, urine, and spinal fluid samples.
Study NCT05969366 — intervention group
Intervention type: PROCEDURE
Intervention: Total hip arthroplasty
Study NCT05427097 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Helical® patches
Description: Active Helical® patches and non-active patches (placebo) are placed at cervical tension points
Study NCT00953420 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EBV-specific cytotoxic T lymphocytes
Description: 1 x 10e8 cells/m2 IV over 1 to 5 min
Study NCT00953420 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: G-CSF or Peg-GCSF
Description: If needed per dose modification guidelines: Peg-GCSF 0.1 mg/kg ≤ 45 kg; 6 mg for > 45 kg subcutaneous on Day 2 or GCSF 5 mcg/kg/day (max of 600 mcg) subcutaneous to start 24 hours after carboplatin administration until ANC > 2500 cells/ul x 2 days after nadir.
Study NCT01586338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hylan G-F 20
Description: Intra-articular injection (pre-filled glass syringe)
Study NCT01436123 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stenting and micro-infusion of NP
Description: Step 1 - IVUS, OCT-guided put in everolimus-eluting (drug-eluting-DES) stent + intravascular ultrasound (IVUS) mapping + harvesting stem cells with mesenchymal phenotype; Step 2 - culturing of stem cells in medium by gold nanoparticles with silica-iron oxide shells; Step 3 - micro-infusion of stem cells bearing NP into the lesion; Step 4 - detonation of nanoshells after migration of stem cells with NPs inside (until 7-10 days after transplantation). We expect 'melting' and 'burning' effects of PPTT, beneficial effects of bioactive products of stem cells lysis + benefits from further migration of stem cells from patch into the plaque
Study NCT01436123 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implantation of everolimus-eluting stent
Description: Put stent in ischemia-related coronary artery by indications for PCI
Study NCT00453102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: IV Infusion of 250mg/m² of Rituximab Within 4 hours on Days 1, 7, 8, 9 0.4 millicuries (mCi)/kilogram (kg) (14.8 megabecquerels (MBq)/kilogram (kg)) for patients with normal platelet count 0.3 mCi/kg (11.1 MBq/kg) for patients with platelet count of 100,000-149,000 cells/mm³
Study NCT00453102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibritumomab Tiuxetan
Description: IV injection of Y-90 Zevalin® over 10 minutes on Days 1, 7, 8, 9:~0.4 mCi/kg (14.8 MBq/kg) for patients with normal platelet count 0.3 mCi/kg (11.1 MBq/kg) for patients with platelet count of 100,000-149,000 cells/mm³
Study NCT05171140 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Triangular Nail Placement of Femoral Neck
Description: Triangular Nail Placement of Femoral Neck in arm A Femoral Neck Inverted Triangle Nail Surgery in arm B
Study NCT03051659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin Mesylate
Description: Eribulin mesylate is developed from a natural substance found in a sea sponge. Eribulin mesylate works by preventing cancer cells from multiplying
Study NCT03051659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells.
Study NCT02660762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: induction therapy I：1.4 mg/m2 IV d1, 8, 15, 22； consolidation therapy(Cycle 1)：1.4 mg/m2 IV d1, 8, 15, 22； Maintenance therapy: 1.4 mg/m2 intravenously every 3 months for a total of 2.5 years
Study NCT02660762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: induction therapy I：60 mg/m2 IV d1, 8, 15, 22； consolidation therapy(Cycle 3)：25 mg/m2 IV d1, 8, 15, 22；
Study NCT02660762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: induction therapy I: 2500U/m2,im,d8,22 Intensification therapy:2500U/m2 im, d2,23 consolidation therapy(Cycle 2，4)：2500U/m2 im, d1
Study NCT05427097 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Helical® patches
Description: Active Helical® patches and non-active patches (placebo) are placed at cervical tension points
Study NCT02872649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran
Study NCT02660762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: induction therapy I：60 mg/m2 PO d1-28; Maintenance therapy:prednisone 60 mg/m2 orally for 5 days every 3 months for a total of 2.5 years
Study NCT02660762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal Methotrexate
Description: induction therapy I：12.5 mg IT d15 induction therapy II：12.5 mg IT d1, 8, 15, 22
Study NCT02660762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: induction therapy II:650 mg/m2 IV d1, 15, 29 consolidation therapy(Cycle 3)：650 mg/m2 IV，d29